Swiss biotechnology firm Anaveon has appointed Thaminda Ramanayake as its new Chief Executive Officer, signaling a strategic move to accelerate its clinical development. Ramanayake, a seasoned biopharmaceutical executive, joins the company as it advances its pipeline of precision immunology biologics. His leadership is expected to guide Anaveon through a critical growth phase focused on addressing autoimmune and inflammatory diseases.
A Strategic Leader for Clinical Advancement
Thaminda Ramanayake brings over two decades of global biopharmaceutical leadership to his new role at Anaveon. His extensive background includes a pivotal tenure as Chief Business Officer at CureVac, where he was instrumental in its transformation and subsequent acquisition by BioNTech. His career also features senior strategy and business development positions at industry giants like Sanofi, BioMarin, and Amgen.
The Anaveon Board of Directors highlighted Ramanayake's proven expertise in strategic transactions and value creation as key to his appointment. Board Chair Dieter Weinand stated that his skills are ideally suited to guide the company as it prepares to move its immunology programs into the clinic. This appointment reflects the board's confidence in his ability to steer Anaveon toward becoming a premier immunology company.
Sharpening Focus on Immunological Innovation
Anaveon is dedicated to reprogramming the immune system to treat conditions with significant unmet medical needs. The Basel-based company develops precision biologics that target central regulatory nodes to restore a durable immune balance. This focused approach aims to selectively eliminate or reprogram pathogenic immune cells in autoimmune and inflammatory disorders.
In his statement, Ramanayake emphasized the potential of Anaveon's growing pipeline, particularly its lead asset, ANV200. This candidate is being developed as a best-in-class therapy for the robust depletion of pathogenic T cells. The promising data across its portfolio presents a tremendous opportunity to make a meaningful difference for patients worldwide.
A Vision for Future Growth
Accepting his new position, Ramanayake described it as an honor and an exciting challenge to lead the company forward. He expressed his eagerness to partner with the existing team to drive the next stage of growth and innovation. His vision centers on leveraging the company's strong scientific foundation to translate promising research into impactful patient therapies.
The company's internal leadership shares this optimism for the future under new guidance. Chief Science Officer Christoph Huber noted that Anaveon is well-positioned to develop differentiated therapies based on its scientific expertise. He added that the team looks forward to collaborating with Ramanayake to deliver these new treatments to patients.
Acknowledging a Foundational Legacy
The leadership change marks a new chapter for Anaveon, as Ramanayake takes the helm from Andreas Katopodis. Katopodis has guided the company since its launch, establishing the scientific and operational groundwork for its current success. He expressed pride in the foundation that has been built and confidence in the company's future direction.
On behalf of the board, Dieter Weinand extended his gratitude to Andreas Katopodis for his significant contributions. He recognized Katopodis for leading Anaveon from a concept to a company with a portfolio of promising programs. This transition acknowledges the foundational work that has positioned Anaveon for its next stage of development and growth.
The appointment of Thaminda Ramanayake as CEO represents a pivotal moment for Anaveon as it transitions from a preclinical to a clinical-stage company. With his extensive experience in corporate strategy and transactions, the company is poised to advance its innovative immunology pipeline. The industry will be watching closely as Anaveon leverages this new leadership to pursue its mission of delivering transformative therapies.